UCLA

UCLA Previously Published Works

Title

Response to Letter About Memory and Brain Effects of Curcumin.

Permalink

<https://escholarship.org/uc/item/2n79774h>

Journal

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 26(6)

ISSN

1064-7481

Authors

Siddarth, Prabha
Barrio, Jorge R
Small, Gary W

Publication Date

2018-06-01

DOI

10.1016/j.jagp.2018.03.014

Peer reviewed

Response to Letter About Memory and Brain Effects of Curcumin

TO THE EDITOR:

Considerable disagreement exists on the necessity and extent of adjustment for multiple comparisons.¹ Although many articles have discussed when and how to control for inflation of Type I errors (i.e., finding a difference between groups when none exists), there is no consensus in the literature regarding this issue.^{2–4} It has been pointed out, however, that adjustment is not required when the research is addressing novel or exploratory hypotheses—that is, when one also needs to consider the risk of making a Type II error (i.e., finding no difference when one exists).^{2,5} Adjusting only for Type I error increases the risk for Type II error.⁶

Schulz and Grimes⁷ recommend restricting the number of primary end points tested and confining significance testing to only those hypotheses specified beforehand. If such primary outcomes have been specified beforehand, then correcting for multiplicity may be too conservative and should be avoided. As detailed in our report,⁸ we specify our primary (Buschke Selective Reminding Test for verbal memory, Brief Visual Memory Test-Revised for visual memory) and secondary (Trail Making Test Part A) outcome measures and then present results for these prespecified outcome measures without correction. Further, we point out that we did not correct for multiple tests because this was a pilot study, thus following the recommendation of Streiner and Norman,¹ who

note that exploratory studies addressing a small number of hypotheses do not require such corrections. Moreover, by emphasizing effect sizes in our results, the multiplicity problem further diminishes in impact.

Regarding the comments about between-group differences, these are typically the primary metric by which the results of a clinical trial are evaluated; however, as has been noted, both in the case when the primary outcome is positive⁹ and when the primary outcome fails,¹⁰ a more detailed examination of the totality of the evidence is warranted. Within-group changes are both informative and clinically relevant, especially in the context of a pilot study. By presenting all results, which we clearly indicate as between-group or within-group, readers are provided all relevant information regarding within-treatment as well as between-treatment outcome variability and can therefore make their own judgment as to the clinical significance of the treatment.

Dacruz et al. also comment that the low dropout rate in our study suggests that the sample is atypical, although other clinical trials using supplements with minimal side effects in people with mild age-related memory complaints¹¹ have demonstrated comparably low dropout rates.

Our interpretation that FDDNP binding reflects brain accumulation of both amyloid and tau neuroaggregates was also questioned by citing research based on computer simulations examining FDDNP binding to A β fibrils and A β monomers, resolved from solid-state nuclear magnetic resonance experiments.¹² A cursory reading

of this research suggests that the authors established three conclusions:

- (a) Their computer simulations suggest that FDDNP ligands bind with high affinity to A β fibrils—as already demonstrated experimentally with in vitro fibril determinations, X-ray crystallography, and human brain tissue specimens, as well as positron emission tomography in the brain of living subjects.^{13–18} Moreover, hydrophobic effects coupled with π -stacking interactions are the dominant factors governing FDDNP binding.¹⁶
- (b) FDDNP binds to two distinct sites on the A β fibril.
- (c) Computer simulations reveal a strong tendency of bound FDDNP molecules for self-aggregation at millimolar (32 mM) FDDNP concentrations, which were used for these computer simulations. These concentrations are more than 10^6 to 10^9 times higher than the concentrations of FDDNP (or other PET ligands) used in in vitro or in vivo experiments, which explains the suggestion for possible FDDNP binding to A β monomers, facilitated by aggregation, which typically occurs at high concentrations (e.g., $>10^{-4}$ M).

Using an integrated approach including molecular docking, molecular dynamics, and energy calculations to investigate site-specific interactions of different amyloid binding molecules, Murugan et al.¹⁹ recently further confirmed experimental evidence of FDDNP binding to A β fibrils.

We have no direct evidence that FDDNP can bind curcumin in vivo or that curcumin may interfere with the FDDNP PET signal. Nevertheless, it is essential to consider and exclude any possible interactions between the probe under investigation and any pharmacological agent used by the research subjects at the time of the PET determination. As we note in our report, we are not certain how curcumin may exert cognitive and mood effects, and curcumin's very low brain permeability points to factors other than direct amyloid or tau binding as more likely explanations for curcumin's brain health effects. Abundant evidence indicates that curcumin's in vivo central effect of reducing amyloid accumulation might derive from multiple activities beyond direct binding inhibition of aggregate formation. These curcumin effects may be mediated through the gut-controlled inflammatory processes in the body, involving multiple pathways such as metal chelation; limitation of oxidative damage; and reduction of cholesterol, proinflammatory cytokines, and lipids.⁸ In support of an anti-inflammatory mechanism is a very recent study showing that curcumin prevented acute neuro-inflammation and long-term memory impairment in laboratory mice.²⁰

We have been cautious in interpreting these observed curcumin benefits and have stressed that the relatively small sample size in our study warrants caution in interpreting our results. The finding that curcumin consumption compared with placebo benefits clinical symptoms is consistent with our a priori hypotheses, and the observation that it independently leads to less

FDDNP binding in two key components of the limbic system—the amygdala and the hypothalamus—further supports these cognitive findings, however. The role of the amygdala in memory processing, decision-making, and emotional responses, in conjunction with the role of the hypothalamus in the innervation of cortical regions involved in Alzheimer disease, cannot be ignored or dismissed. A future study in a larger sample would certainly provide additional insight on curcumin's effects on memory and its mode of action.

*Prabha Siddarth, Ph.D.,
Jorge R. Barrio, Ph.D.,
Gary W. Small, M.D.
Department of Psychiatry and
Biobehavioral Sciences, UCLA
Longevity Center, Semel Institute for
Neuroscience and Human Behavior,
Department of Molecular and Medical
Pharmacology, David Geffen School of
Medicine at the University of
California Los Angeles, Los Angeles,
CA*

References

1. Streiner DL, Norman RG: Correction for multiple testing: is there a resolution? *Chest* 2011; 140:16–18
2. Bender R, Lange S: Adjusting for multiple testing—when and how? *J Clin Epidemiol* 2001; 54:343–349
3. Proschan MA, Waclawiw MA: Practical guidelines for multiplicity adjustment in clinical trials. *Control Clin Trials* 2000; 21:527–539
4. Gelman A, Hill J, Yajima M: Why we (usually) don't have to worry about multiple comparisons. *J Res Educ Eff* 2012; 5:189–211
5. Perneger TV: Adjusting for multiple testing in studies is less important than other concerns. *BMJ* 1999; 318:1288
6. Rothman KJ: No adjustments are needed for multiple comparisons. *Epidemiol* 1990; 1:43–46
7. Schulz KF, Grimes DA: Multiplicity in randomized trials I: endpoints and treatments. *Lancet* 2005; 365:1591–1595
8. Small GW, Siddarth P, Li Z, et al: Memory and brain amyloid and tau effects of a bioavailable form of curcumin in nondemented adults: a double-blind, placebo-controlled 18-month trial. *Am J Geriatr Psychiatry* 2018; 26:266–277
9. Pocock SJ, Stone GW: The primary outcome is positive—is that good enough? *N Engl J Med* 2016; 375:971–979
10. Pocock SJ, Stone GW: The primary outcome fails—what next? *N Engl J Med* 2016; 375:861–870
11. Herrlinger KA, Nieman KM, Sanoshy KD, et al: Spearmint extract improves working memory in men and women with age-associated memory impairment. *J Altern Complement Med* 2018; 24:37–47
12. Parikh ND, Klimov DK: Molecular mechanisms of Alzheimer's biomarker FDDNP binding to Aβ amyloid fibril. *J Phys Chem B* 2015; 119:11568–11580
13. Barrio JR, Huang SC, Cole G, et al: PET imaging of tangles and plaques in Alzheimer disease with a highly hydrophobic probe. *J Labelled Comp Radiopharm* 1999; 42:S194–S195
14. Agdeppa E, Kepe V, Liu J, et al: Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidenederivatives as positron emission tomography imaging probes for β-amyloid plaques in Alzheimer's disease. *J Neurosci* 2001; 21:1–5
15. Agdeppa ED, Kepe V, Petri A, et al: In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-{6-[(2-[18F]fluoroethyl) (methylamino)-2-naphthyl]- ethylidene) malononitrile. *Neuroscience* 2003; 117:723–730
16. Shoghi-Jadid K, Small GW, Agdeppa ED, et al: Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. *Am J Geriatr Psychiatry* 2002; 10:24–35
17. Landau M, Sawaya MR, Faull KF, et al: Towards a pharmacophore for amyloid. *PLoS Biol* 2011; 9:e1001080
18. Smid LM, Vovko TD, Popovic M, et al: The 2,6-Disubstituted naphthalene derivative FDDNP labeling reliably predicts Congo Red birefringence of protein deposits in brain sections of selected human neurodegenerative diseases. *Brain Pathol* 2006; 16:124–130
19. Murugan NA, Hallidin C, Nordberg A, et al: The culprit is in the cave: the core sites explain the binding profiles of amyloid-specific tracers. *J Phys Chem Lett* 2016; 7:3313–3321
20. Sorrenti V, Contarini G, Sut S, et al: Curcumin prevents acute neuroinflammation and long-term memory impairment induced by systemic lipopolysaccharide in mice. *Front Pharmacol* 2018; doi:10.3389/fphar.2018.00183